FDx Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

FDx Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,040	Closed	-$251K	–	828
2023 Q1	$251K	Hold	7,040	–	–	0.01%	634
2022 Q4	$251K	Sell	7,040 -211	-3%	-$7.33K	0.01%	634
2022 Q3	$245K	Sell	7,251 -388	-5%	-$12.6K	0.01%	620
2022 Q2	$221K	Sell	7,639 -127	-2%	-$3.64K	0.01%	742
2022 Q1	$251K	Buy	7,766 +733	+10%	+$22.5K	0.01%	723
2021 Q4	$205K	Buy	+7,033	New	+$213K	0.01%	827
2018 Q1	–	Sell	-5,544	Closed	-$221K	–	1256
2017 Q4	$221K	Buy	5,544 +53	+1%	+$2.09K	0.01%	1160
2017 Q3	$220K	Sell	5,491 -548	-9%	-$23.7K	0.01%	1177
2017 Q2	$260K	Buy	+6,039	New	+$215K	0.01%	1038

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FDx Advisors's SUPN Position: Q2 2023 in Review

FDx Advisors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 7,040 shares — an estimated $251K sold.

FDx Advisors first reported a position in SUPN in Q2 2017 and held it in 9 quarters. The position peaked at $260K in Q2 2017. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

FDx Advisors reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
FDx Advisors sold 7,040 Supernus Pharmaceuticals shares in Q2 2023, an estimated $251K.
FDx Advisors first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 9 quarters.
FDx Advisors's Supernus Pharmaceuticals position peaked at $260K in Q2 2017.
249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on FDx Advisors's 13F filing for Q2 2023, filed 17 Jul 2023.